Vertex trial for hypoglycaemia therapy shows early promise
New data now reveals significant increases in the blood glucose time-in-range compared to baseline, following VX-880 dosage
Read More
Tag: hypoglycaemia
Zealand Pharma’s hypoglycaemia therapy Zegalogue scores approval in the US
Therapy authorised for the treatment of severe hypoglycaemia in people with diabetes
Read More
Study shows reduced hypoglycaemia after switch to Tresiba
Novo Nordisk’s Tresiba has been found to be efficient in treating diabetes compared to other basal insulins.
Read More
Novo Nordisk’s Tresiba backed for use on NHS Wales
Novo Nordisk’s long-acting insulin Tresiba has been approved for routine use by NHS Wales as an option for treating diabetes.
Read More
Novo’s Tresiba beats Sanofi’s Lantus on reducing hypoglycaemia
Novo Nordisk has showcased new data from two Phase IIIb trials showing that diabetes patients treated with Tresiba experienced significantly lower rates of several types of hypoglycaemia than those using Sanofi’s Lantus.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
